{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:19:00Z","timestamp":1791357540495,"version":"4.3.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"20","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00213-017-4685-7","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T20:23:25Z","timestamp":1501705405000},"page":"3075-3081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["A comparative study of QT prolongation with serotonin reuptake inhibitors"],"prefix":"10.1007","volume":"234","author":[{"given":"Ana","family":"Ojero-Senard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Benevent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bondon-Guitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Chebane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"4685_CR1","doi-asserted-by":"crossref","unstructured":"Anderson, I. M., Nutt, D. J. and Deakin, JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology Guidelines. J Psychopharmacol, 2000; 14, 3\u201320","DOI":"10.1177\/026988110001400101"},{"key":"4685_CR2","unstructured":"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm297391.htm"},{"key":"4685_CR3","unstructured":"FDA Drug Safety Communication: Clarification of dosing and warning recommendations for Celexa http:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/SpecialFeatures\/ucm297764.htm"},{"key":"4685_CR4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/appi.ajp.2016.15111444","volume":"173","author":"TS Rector","year":"2016","unstructured":"Rector TS, Adabag S, Cunningham F, Nelson D, Dieperink E (2016) Outcomes of citalopram dosage risk mitigation in a veteran population. Am J Psychiatry 173:896\u2013902","journal-title":"Am J Psychiatry"},{"key":"4685_CR5","doi-asserted-by":"crossref","first-page":"f288","DOI":"10.1136\/bmj.f288","volume":"346","author":"VM Castro","year":"2013","unstructured":"Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH (2013) QT interval and antidepressant use: a cross sectional study of electronic health records. Br Med J 346:f288","journal-title":"Br Med J"},{"key":"4685_CR6","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1176\/appi.ajp.2013.12060860","volume":"170","author":"FR Girardin","year":"2013","unstructured":"Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P (2013) Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG screening outcome in psychiatry study. Am J Psychiatry 170:1468\u20131476","journal-title":"Am J Psychiatry"},{"key":"4685_CR7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1176\/appi.ajp.2013.12030408","volume":"170","author":"K Zivin","year":"2013","unstructured":"Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, Kales HC (2013) Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 170:642\u2013650","journal-title":"Am J Psychiatry"},{"key":"4685_CR8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/pds.2181","volume":"20","author":"CE Leonard","year":"2011","unstructured":"Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S (2011) Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Safety 20:903\u2013913","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"4685_CR9","doi-asserted-by":"crossref","first-page":"d4551","DOI":"10.1136\/bmj.d4551","volume":"343","author":"C Coupland","year":"2011","unstructured":"Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. Br Med J 343:d4551","journal-title":"Br Med J"},{"key":"4685_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","volume":"22","author":"A Bate","year":"2008","unstructured":"Bate A, Lindquist M, Edwards IR (2008) The application of knowledge discovery in database to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 22:127\u2013140","journal-title":"Fundam Clin Pharmacol"},{"key":"4685_CR11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u20131259","journal-title":"Lancet"},{"key":"4685_CR12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.therap.2016.02.029","volume":"71","author":"T Vial","year":"2016","unstructured":"Vial T (2016) French pharmacovigilance: missions, organization and perspectives. Therapie 71:143\u2013150","journal-title":"Therapie"},{"key":"4685_CR13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","volume":"71","author":"G Miremont-Salam\u00e9","year":"2016","unstructured":"Miremont-Salam\u00e9 G, Th\u00e9ophile H, Haramburu F, B\u00e9gaud B (2016) Causality assessment in pharmacovigilance: the French method and its successive updates. Therapie 71:179\u2013186","journal-title":"Therapie"},{"key":"4685_CR14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H (2011) Lapeyre-Mestre benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908","journal-title":"Br J Clin Pharmacol"},{"key":"4685_CR15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1472-8206.2010.00871.x","volume":"25","author":"A Perrin-Terrin","year":"2011","unstructured":"Perrin-Terrin A, Pathak A, Lapeyre-Mestre M (2011) QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol 25:503\u2013510","journal-title":"Fundam Clin Pharmacol"},{"key":"4685_CR16","unstructured":"Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, Gibaja V, Caous AS, Eiden C, Authier N, Le Boisselier R, Guerlais M, Jouanjus \u00c9, Lepelley M, Pizzoglio V, Pain S, Richard N, Micallef J; le R\u00e9seau fran\u00e7ais d\u2019addictovigilance. Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network. Therapie. 2017 Feb 22. pii: S0040\u20135957(17)30042\u20132"},{"key":"4685_CR17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.2011.368","volume":"92","author":"P Weeke","year":"2012","unstructured":"Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, Fosb\u00f8l EL, Larsen JK, Lippert FK, Nielsen SL, Gerds T, Andersen PK, Kanters JK, Poulsen HE, Pehrson S, K\u00f8ber L, Torp-Pedersen C (2012) Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 92:72\u201379","journal-title":"Clin Pharmacol Ther"},{"key":"4685_CR18","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1177\/1060028013501994","volume":"47","author":"KA Funk","year":"2013","unstructured":"Funk KA, Bostwick JR (2013) A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 47:1330\u20131341","journal-title":"Ann Pharmacother"},{"key":"4685_CR19","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.4088\/JCP.13r08672","volume":"75","author":"SR Beach","year":"2014","unstructured":"Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC (2014) Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 75:e441\u2013e449","journal-title":"J Clin Psychiatry"},{"key":"4685_CR20","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/bcp.12681","volume":"80","author":"NM Maljuric","year":"2015","unstructured":"Maljuric NM, Noordam R, Aarts N, Niemeijer MN, van den Berg ME, Hofman A, Kors JA, Stricker BH, Visser LE (2015) Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study. Br J Clin Pharmacol 80:698\u2013705","journal-title":"Br J Clin Pharmacol"},{"key":"4685_CR21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/pds.1607","volume":"17","author":"C Astr\u00f6m-Lilja","year":"2008","unstructured":"Astr\u00f6m-Lilja C, Odeberg JM, Ekman E, H\u00e4gg S (2008) Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 17:587\u2013592","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4685_CR22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.encep.2013.07.003","volume":"41","author":"F Montastruc","year":"2015","unstructured":"Montastruc F, Rieu J, Letamendia C, Montastruc JL, Pathak A, Schmitt L (2015) Measurement of QT interval and serotoninergic reuptake inhibitor antidepressants: a study in a university psychiatric hospital. Enc\u00e9phale 41:282\u2013283","journal-title":"Enc\u00e9phale"},{"key":"4685_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.psym.2014.09.002","volume":"56","author":"RR Tampi","year":"2015","unstructured":"Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, May J (2015) Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics 56:36\u201343","journal-title":"Psychosomatics"},{"key":"4685_CR24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","volume":"89","author":"YG Yap","year":"2003","unstructured":"Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89:1363\u20131372","journal-title":"Heart"},{"key":"4685_CR25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.therap.2016.02.016","volume":"71","author":"JL Faillie","year":"2016","unstructured":"Faillie JL, Montastruc F, Montastruc JL, Pariente A (2016) Pharmacoepidemiology and its input to pharmacovigilance. Therapie 71:211\u2013216","journal-title":"Therapie"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4685-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4685-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4685-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:42:27Z","timestamp":1602632547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4685-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":25,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["4685"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4685-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}